|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University of Illinois |
|---|---|
| Information provided by: | University of Illinois |
| ClinicalTrials.gov Identifier: | NCT00716586 |
Purpose
Seven patients with X-linked retinoschisis were treated with dorzolamide and the response to this treatment was monitored using OCT. These patients were also tested for the causative gene mutation and the resultant mechanism of functional loss of retinoschisin. It was observed that a response to dorzolamide may be seen irrespective of the mechanism that leads to decrease in function of retinoschisin.
| Condition | Intervention | Phase |
|---|---|---|
|
Juvenile X-Linked Retinoschisis |
Drug: dorzolamide |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
| Official Title: | Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration |
| Estimated Enrollment: | 15 |
| Study Start Date: | October 2005 |
| Estimated Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Patients over the age of 18 years with juvenile X-linked retinoschisis
|
Drug: dorzolamide
2% dorzolamide- 1 Gtt TID
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Gerald A Fishman, MD | 312.996.8939 | gerafish@uic.edu |
| United States, Illinois | |
| University of Illinois Medical Center | Recruiting |
| Chicago, Illinois, United States, 60612 | |
| Contact: Gerald A Fishman, MD 312-996-8939 gerafish@uic.edu | |
More Information
| Responsible Party: | University of Illinois at Chicago ( Gerald Fishman, MD ) |
| Study ID Numbers: | IRB-2005-0551 |
| Study First Received: | July 14, 2008 |
| Last Updated: | July 14, 2008 |
| ClinicalTrials.gov Identifier: | NCT00716586 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Macular Edema Carbonic Anhydrase Inhibitors Retinoschisis Eye Diseases Macular Degeneration Edema |
Retinal Degeneration Cardiovascular Agents Antihypertensive Agents Retinal Diseases Dorzolamide |
|
Retinoschisis Molecular Mechanisms of Pharmacological Action Eye Diseases Retinal Degeneration Macular Degeneration Enzyme Inhibitors Cardiovascular Agents |
Antihypertensive Agents Pharmacologic Actions Macular Edema Carbonic Anhydrase Inhibitors Therapeutic Uses Retinal Diseases Dorzolamide |
